Overview

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Status:
Active, not recruiting

Trial end date:
2024-03-29

Target enrollment:

Participant gender:

Summary

This study aims to assess efficacy of Niraparib (GSK3985771) as maintenance treatment in participants with Stage III or IV ovarian cancer. Participants must have completed front-line platinum based regimen with complete (CR) or partial response (PR). Data collection for Secondary Outcome measures is ongoing and the approximate duration of the study will be 7 years.

Phase:

Phase 3

Details

Lead Sponsor:

Tesaro, Inc.

Collaborators:

European Network of Gynaecological Oncological Trial Groups (ENGOT)
Gynecologic Oncology Group
Myriad Genetics, Inc.

Treatments:

Niraparib